Billions on the line, Novartis and Amgen exchange broadsides as Aimovig partnership erupts into a legal war
Novartis has had nothing but upbeat things to say about their hot new migraine drug Aimovig and the reengineered collaboration pact with Amgen back in 2017 that gave them half of the lucrative US market.
Until today.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.